Form 4: Cytek Biosciences SVP, Global Sales and Services, Philippe Busque, Reports Changes in Beneficial Ownership

Philippe Busque, SVP at Cytek Biosciences, reports transactions involving common stock and restricted stock units, resulting in adjustments to his beneficial ownership.

Summary

• On March 10, 2025, Philippe Busque, SVP of Global Sales and Services at Cytek Biosciences, executed transactions involving the company's common stock and restricted stock units (RSUs).
• These transactions included the vesting of RSUs, the acquisition of common stock upon vesting, and the surrender of shares to cover tax obligations.
• Specifically, 2,049 and 2,946 RSUs vested, resulting in the acquisition of the same number of common stock shares.
• A total of 1,947 shares were withheld to satisfy tax obligations at a price of $4.36 per share.
• Following these transactions, Busque's direct ownership of Cytek Biosciences common stock is 15,919 shares and 26,521 Restricted Stock Units.

Sentiment

Score: 5

Explanation: This is a neutral report on stock transactions related to executive compensation. It doesn't inherently indicate positive or negative sentiment.

Industry Context

This filing is a routine disclosure related to executive compensation and stock-based awards, common in publicly traded companies. It provides transparency into the transactions of company insiders.

Stakeholder Impact

• The transactions have a minor impact on the total outstanding shares of Cytek Biosciences.
• The filing provides transparency to shareholders regarding executive compensation.

Key Dates